A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort

European Journal of Preventive Cardiology

Volumn 20, Issue 1, 2013, Pages 98-106

  Colkesen, Ersen B ^a   Jørstad, Harald T ^a   Peters, Ron J G ^a   Boekholdt, S Matthijs ^a   Tijssen, Jan G P ^a   Ferket, Bart S ^b   Wareham, Nicholas J ^c   Khaw, Kay Tee ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cardiovascular risk management; guidelines; primary prevention

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; NUMBERS NEEDED TO TREAT; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84873932279     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/2047487311435456     Document Type: Article

References (23)

1. Allender S, Scarborough P, Peto S et al. European cardiovascular disease statistics 2008. British Heart Foundation Health Promotion Research Group Department of Public Health, University of Oxford, European Heart Network, 2008.
2. Jackson R, Lynch J, Harper S. Preventing coronary heart disease. BMJ. 2006 ; 332: 617-18
3. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005 ; 365: 434-41
4. Ferket BS, Colkesen EB, Visser JJ, et al. Systematic review of guidelines on cardiovascular risk assessment: which recommendations should clinicians follow for a cardiovascular health check?. Arch Intern Med. 2010 ; 170: 27-40
5. NICE clinical guideline 67 lipid modification:cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: NICE ; 2008 :
6. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007 ; 28: 2375-414
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
8. Grilli R, Magrini N, Penna A, et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet. 2000 ; 355: 103-6
9. van Dis I, Kromhout D, Geleijnse JM, et al. Evaluation of cardiovascular risk predicted by different SCORE equations: the Netherlands as an example. Eur J Cardiovasc Prev Rehabil. 2010 ; 17: 244-9
10. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999 ; 80 (Suppl 1). 95-103
11. Boekholdt SM, Peters RJ, Day NE, et al. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med. 2004 ; 117: 390-7
12. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991 ; 121 (1 Pt 2). 293-8
13. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 ; 97: 1837-47
14. Chamnan P, Simmons RK, Khaw KT, et al. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ. 2010 ; 340: c1693.
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
16. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-78
17. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009 ; 150: 243-54
18. Broedl UC, Geiss HC, Parhofer KG. Comparison of current guidelines for primary prevention of coronary heart disease: risk assessment and lipid-lowering therapy. J Gen Intern Med. 2003 ; 18: 190-5
19. Fornasini M, Brotons C, Sellares J, et al. Consequences of using different methods to assess cardiovascular risk in primary care. Fam Pract. 2006 ; 23: 28-33
20. Manuel DG, Kwong K, Tanuseputro P, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. BMJ. 2006 ; 332: 1419-1419
21. Nanchen D, Chiolero A, Cornuz J, et al. Cardiovascular risk estimation and eligibility for statins in primary prevention comparing different strategies. Am J Cardiol. 2009 ; 103: 1089-95
22. Unwin N, Thomson R, O'Byrne AM, et al. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ. 1998 ; 317: 1125-30
23. McElduff P, Jaefarnezhad M, Durrington PN. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart. 2006 ; 92: 1213-18